TABLE 2.
Cytotoxic activity of synthesized compounds (1a–1j).
| Cpds | HepG2 | MCF-7 | HeLa | ||||||
|
|
|
|
|||||||
| GI50 (μm) | TGI (μm) | LC50 (μm) | GI50 (μm) | TGI (μm) | LC50 (μm) | GI50 (μm) | TGI (μm) | LC50 (μm) | |
| 1a | 43.2 | 78.3 | >100 | – | – | >100 | – | – | 100 |
| 1b | 42.2 | 23.1 | 56.8 | 46.1 | 85.1 | >100 | 51.0 | 89.2 | >100 |
| 1c | 36.3 | 65.3 | 0.9 | – | – | 0.55 | 41.3 | 87.2 | 0.50 |
| 1d | 01.0 | 0.25 | 54.0 | 0.89 | 09.3 | 65.0 | 08.9 | 06.8 | 0.50 |
| 1e | 15.9 | 38.2 | 44.8 | 24.4 | 59.3 | 66.3 | 34.2 | 72.1 | >100 |
| 1f | 29.1 | 46.8 | 57.5 | 18.6 | 41.8 | 42.3 | 21.6 | 54.7 | 77.4 |
| 1g | 48.0 | 61.3 | 59.3 | 34.0 | 67.4 | 30.5 | 37.9 | 51.9 | 58.9 |
| 1h | 21.3 | 41.0 | 72.1 | 12.9 | 45.3 | 10.3 | 52.9 | 81.3 | >100 |
| 1i | 19.3 | 28.3 | >100 | 45.6 | 56.0 | 59.3 | 49.0 | 49.3 | 55.0 |
| 1j | 40.3 | 45.3 | 66.8 | 56.0 | 49.3 | 78.6 | 2.3 | 58.3 | 48.3 |
| Doxorubicin (standard) | 0.01 | 0.13 | 0.58 | 0.02 | 0.21 | 0.74 | 0.05 | 0.41 | 0.88 |